China Biologic Comments on the Proposed Shanghai RAAS Transaction PR Newswire BEIJING, May 24, 2013 BEIJING, May 24, 2013 /PRNewswire-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company has recently learned from a public announcement issued by Shanghai RAAS Blood Products Co., Ltd. ("Shanghai RAAS"), a public company listed on Shenzhen Stock Exchange, that on May 21, 2013, Ms. Siu Ling Chan ("Ms. Chan"), one of the shareholders of the Company, and her spouse, Mr. Tung Lam, entered into a stock purchase agreement with Shanghai RAAS. According to the stock purchase agreement, Ms. Chan agreed to sell to Shanghai RAAS an aggregate of 2,657,660 shares of the Company's common stock, representing 9.9% of the Company's outstanding shares (the "Proposed Shanghai RAAS Transaction"). Pursuant to Shanghai RAAS corporate regulations and Chinese law, the transaction is subject to obtaining approval from Shanghai RAAS's shareholders and all necessary governmental authorities or agencies, as well as satisfying certain other closing conditions. Shanghai RAAS also stated in its announcement it has an intention to develop strategic business cooperation with the Company. China Biologic would like to clarify that the Company had no knowledge of the Proposed Shanghai RAAS Transaction prior to the public announcement issued by Shanghai RAAS, nor has the Company had any communication or discussion with Shanghai RAAS regarding this transaction. The Company considers Shanghai RAAS as one of its direct competitors in China and therefore does not view the Proposed Shanghai RAAS Transaction as a viable transaction. Given the competition between Shanghai RAAS and the Company and the differences between the two companies in terms of business strategies and technological capabilities, the Company currently has no intention to discuss or explore any business cooperation with Shanghai RAAS. As disclosed in Shanghai RAAS' public announcement, it is apparent that Shanghai RAAS is aware of the fact that Ms. Chan's shareholding status with the Company is under dispute in a pending case in Hong Kong. As previously disclosed by the Company on March 12, 2013 on a Form 8-K filed with the United States Securities and Exchange Commission, the Company was notified, by a Hong Kong solicitors firm representing a group of individuals, of a litigation (the "Hong Kong Litigation") filed in the High Court of Hong Kong against Ms. Chan and her spouse, Mr. Tung Lam as well as certain other defendants. Based on information provided by the Hong Kong solicitors firm, the Company understands that up to 5,178,962 shares of the Company's common stock held by Ms. Chan may be brought into question during the Hong Kong Litigation. Based on the Company's shareholder records, Ms. Chan is currently a registered shareholder of 5,362,624 shares of the Company's common stock. China Biologic will closely monitor this case and further developments associated with the Proposed Shanghai RAAS Transaction and reserves the right to take any necessary and appropriate actions, including but not limited to implementing the shareholders rights plan to block the Proposed Shanghai RAAS Transaction. About China Biologic Products, Inc. China Biologic Products, Inc. (Nasdaq: CBPO), is a leading fully integrated plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 plasma-based products through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals and other healthcare facilities in China. For additional information, please see the Company's website www.chinabiologic.com. Safe Harbor Statement This news release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiaries. All statements, other than statements of historical fact included herein, are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions, and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including its potential inability to achieve the expected operating and financial performance in 2012, potential inability to find alternative sources of plasma, potential inability to increase production at permitted sites, potential inability to mitigate the financial consequences of a temporarily reduced raw plasma supply through cost cutting or other efficiencies, and potential additional regulatory restrictions on its operations and those additional risks and uncertainties discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements. Contact: China Biologic Products, Inc. Mr. Ming Yin Vice President Phone: +86-10-6598-3099 Email: firstname.lastname@example.org ICR Inc. Mr. Bill Zima Phone: +86-10-6583-7511 or +1-646-405-5191 E-mail: email@example.com SOURCE China Biologic Products, Inc. Website: http://www.chinabiologic.com
China Biologic Comments on the Proposed Shanghai RAAS Transaction
Press spacebar to pause and continue. Press esc to stop.